Proteomics Partnership Pros Discuss Secret to Success in Industry-Academic Collaborations | GenomeWeb

Collaborations between industry and academia are common in proteomics — but this doesn’t mean these relationships are always happy: There is often a precipitous chasm between the expectations of academic researchers, who are judged by their publications, and those of industry scientists, who have the investors or shareholders on their back and need to protect their intellectual property. How to make these partnerships a success was the main theme of a roundtable discussion at the recent HUPO meeting in Versailles.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.